The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Ashton had been tormented by fear that he would be rejected by his family in the weeks leading up to his coming out in 2012. But his father stood by him through therapy and doctor’s appointments, ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

Neuromodulation and robotics test new stroke recovery therapies. Experts assess research, benefits, and limitations to guide ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...